Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 338

The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.

SARS-CoV-2 Infection of Pluripotent Stem Cell-Derived Human Lung Alveolar Type 2 Cells Elicits a Rapid Epithelial-Intrinsic Inflammatory Response

Open access
Huang, Jessie, Hume, Adam J., Abo, Kristine M., Werder, Rhiannon B., Villacorta-Martin, Carlos, Alysandratos, Konstantinos-Dionysios, Beermann, Mary Lou, Simone-Roach, Chantelle, Lindstrom-Vautrin, Jonathan, Olejnik, Judith, Suder, Ellen L., Bullitt, Esther, Hinds, Anne, Sharma, Arjun, Bosmann, Markus, Wang, Ruobing, Hawkins, Finn, Burks, Eric J., Saeed, Mohsan, Wilson, Andrew A., Mühlberger, Elke, Kotton, Darrell N.·2020·Cell Stem Cell

Published version of a preprint

Abstract

The most severe and fatal infections with SARS-CoV-2 result in the acute respiratory distress syndrome, a clinical phenotype of coronavirus disease 2019 (COVID-19) that is associated with virions targeting the epithelium of the distal lung, particularly the facultative progenitors of this tissue, alveolar epithelial type 2 cells (AT2s). Little is known about the initial responses of human lung alveoli to SARS-CoV-2 infection due in part to inability to access these cells from patients, particularly at early stages of disease. Here we present an in vitro human model that simulates the initial apical infection of the distal lung epithelium with SARS-CoV-2, using AT2s that have been adapted to air-liquid interface culture after their derivation from induced pluripotent stem cells (iAT2s). We find that SARS-CoV-2 induces a rapid global transcriptomic change in infected iAT2s characterized by a shift to an inflammatory phenotype predominated by the secretion of cytokines encoded by NF-kB target genes, delayed epithelial interferon responses, and rapid loss of the mature lung alveolar epithelial program. Over time, infected iAT2s exhibit cellular toxicity that can result in the death of these key alveolar facultative progenitors, as is observed in vivo in COVID-19 lung autopsies. Importantly, drug testing using iAT2s confirmed an antiviral dose-response to remdesivir and demonstrated the efficacy of TMPRSS2 protease inhibition, validating a putative mechanism used for viral entry in human alveolar cells. Our model system reveals the cell-intrinsic responses of a key lung target cell to infection, providing a physiologically relevant platform for further drug development and facilitating a deeper understanding of COVID-19 pathogenesis.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.stem.2020.09.013

Cites

52 of 52 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 1

  1. McCauley, 2018, Derivation of Epithelial-Only Airway Organoids from Human Pluripotent Stem Cells, Curr. Protoc. Stem Cell Biol., 45, e51, 10.1002/cpsc.51 · doi:10.1002/cpsc.51

Cited by

See all 338

Metadata

Authors
Huang, J., Hume, A. J., Abo, K. M., Werder, R. B., Villacorta-Martin, C., Alysandratos, K.-D., Beermann, M. L., Simone-Roach, C., Lindstrom-Vautrin, J., Olejnik, J., Suder, E. L., Bullitt, E., Hinds, A., Sharma, A., Bosmann, M., Wang, R., Hawkins, F., Burks, E. J., Saeed, M., Wilson, A. A., Mühlberger, E., & Kotton, D. N.
Venue
Cell Stem Cell
Publisher
Elsevier BV
Published
2020-12
Volume
27
Issue
6
Pages
962-973.e7
ISSN
  • 1875-9777 (ISSN-L)
  • 1934-5909
OpenAlex
W3087249954
Cited by
338
References
52
FWCI
7.85
Type
journal article
Language
en
Open access
bronze
Licence
Funders
  • National Health and Medical Research Council
  • National Heart, Lung, and Blood Institute
  • Boston University
  • Cystic Fibrosis Foundation (HAWKIN19XX0)
  • Australian Research Council
  • National Institutes of Health (N01 75N92020C00005, F30HL147426)
  • Pulmonary Fibrosis Foundation
  • Gilead Foundation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.